- Pharmaceutical companies
- Incyte
Incyte
Phone: +1 855-446-2983; +1 855-446-2983; +1 302-498-6700
E-mail: bd@incyte.com
Type | Public company |
---|---|
Traded as |
|
Industry | pharmaceutical company |
Founded | 2002 (2002) |
Headquarters | Wilmington, Delaware, U.S. |
Key people | Hervé Hoppenot (CEO, chairman & president) |
Revenue | US$2.99 billion (2021) |
Operating income | US$586 million (2021) |
Net income | US$949 million (2021) |
Total assets | US$4.93 billion (2021) |
Total equity | US$3.77 billion (2021) |
Number of employees | 2,094 (December 2021) |
Website | incyte.com |
Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives. Our drug discovery and development efforts were founded in 2002 in Wilmington, Delaware, by a team of research scientists, chemists and biologists working in immunology. Today, we employ approximately 1500 people and have operations in the U.S., Europe and Japan. Our unique expertise in medicinal chemistry and biology have enabled us to create a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing pipeline of medicines across two franchises: Oncology and Inflammation & Autoimmunity. The commitment of our talented team of world-class scientists to continued scientific excellence has enabled us to identify new molecules, decipher new pathways and develop first-in-class and best-in-class medicines.
For detailed contact information visit location pages below.
Incyte's locations around the world
Clinical Trials sponsored by Incyte
-
Incyte Biosciences UKCompletedAccelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | Blastic Phase Chronic Myelogenous LeukemiaUnited Kingdom, Ireland
-
Incyte Biosciences Japan GKRecruitingDiffuse Large B-cell Lymphoma | Non Hodgkins LymphomaJapan
-
Incyte Biosciences International SàrlCompletedAdvanced MalignanciesUnited States
-
Incyte Biosciences International SàrlTerminatedMetastatic Cancer | Advanced MalignanciesUnited States
-
Incyte Biosciences International SàrlCompletedCervical Cancer | Hepatocellular Carcinoma | Esophageal Cancer | Ovarian Cancer | Mesothelioma | Non-small Cell Lung Cancer (NSCLC) | Urothelial Carcinoma | Merkel Cell Carcinoma | Diffuse Large B-cell Lymphoma | Triple-negative Breast Cancer | Renal Cell Carcinoma (RCC) | Small Cell Lung Cancer (SCLC) | Squamous... and other conditionsUnited States
-
Incyte Biosciences International SàrlWithdrawnBCR-ABL Positive Acute Lymphoblastic LeukemiaGermany, France, Czechia
-
Incyte CorporationNot yet recruiting
-
Incyte CorporationRecruitingHidradenitis Suppurativa (HS)United States, Austria, Belgium, Canada, Germany, Poland, Spain, Australia, Denmark, France, United Kingdom, Japan, Bulgaria, Netherlands, Czechia, Greece, Italy
-
Incyte CorporationRecruitingNonSegmental VitiligoGermany, United States, Italy, Poland, Canada, France, Bulgaria, Hungary, United Kingdom
-
Incyte CorporationRecruitingMyeloproliferative NeoplasmsSpain, Japan, France, Italy, Germany, Australia, United Kingdom, Denmark, Canada